86 related articles for article (PubMed ID: 16246487)
21. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
22. Do Fanconi anemia genes control cell response to cross-linking agents by modulating cytochrome P-450 reductase activity?
Kruyt FA; Youssoufian H
Drug Resist Updat; 2000 Aug; 3(4):211-215. PubMed ID: 11498388
[TBL] [Abstract][Full Text] [Related]
23. Deficiency in incisions produced by XPF at the site of a DNA interstrand cross-link in Fanconi anemia cells.
Kumaresan KR; Sridharan DM; McMahon LW; Lambert MW
Biochemistry; 2007 Dec; 46(50):14359-68. PubMed ID: 18020456
[TBL] [Abstract][Full Text] [Related]
24. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
[TBL] [Abstract][Full Text] [Related]
26. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
[TBL] [Abstract][Full Text] [Related]
28. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
[TBL] [Abstract][Full Text] [Related]
29. Integrative genomics and pathway analysis identified prevalent FA-BRCA pathway alterations in arsenic-associated urinary bladder carcinoma: Chronic arsenic accumulation in cancer tissues hampers the FA-BRCA pathway.
Basu M; Ghosh S; Roychowdhury A; Samadder S; Das P; Addya S; Roy A; Pal DK; Roychoudhury S; Ghosh A; Panda CK
Genomics; 2020 Nov; 112(6):5055-5065. PubMed ID: 32920123
[TBL] [Abstract][Full Text] [Related]
30. FANCF methylation contributes to chemoselectivity in ovarian cancer.
Olopade OI; Wei M
Cancer Cell; 2003 May; 3(5):417-20. PubMed ID: 12781358
[TBL] [Abstract][Full Text] [Related]
31. BRCA1: a missing link in the Fanconi anemia/BRCA pathway.
D'Andrea AD
Cancer Discov; 2013 Apr; 3(4):376-8. PubMed ID: 23580280
[TBL] [Abstract][Full Text] [Related]
32. Intersecting paths to cancer.
Nat Genet; 2004 Apr; 36(4):313. PubMed ID: 15054477
[No Abstract] [Full Text] [Related]
33. Genomic Analysis Made It Possible to Identify Gene-Driver Alterations Covering the Time Window between Diagnosis of Neuroblastoma 4S and the Progression to Stage 4.
Ognibene M; De Marco P; Parodi S; Meli M; Di Cataldo A; Zara F; Pezzolo A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742955
[TBL] [Abstract][Full Text] [Related]
34. Genome Instability in Multiple Myeloma: Facts and Factors.
Aksenova AY; Zhuk AS; Lada AG; Zotova IV; Stepchenkova EI; Kostroma II; Gritsaev SV; Pavlov YI
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885058
[TBL] [Abstract][Full Text] [Related]
35. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
[TBL] [Abstract][Full Text] [Related]
36. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R; Stover DG; Lustberg MB; Shoben A; Zhao M; Mrozek E; Layman RM; Macrae E; Duan W; Zhang J; Hall N; Wright CL; Gillespie S; Berger M; Chalmers JJ; Carey A; Balasubramanian P; Miller BL; Amaya P; Andreopoulou E; Sparano J; Shapiro CL; Villalona-Calero MA; Geyer S; Chen A; Grever MR; Knopp MV; Ramaswamy B
Oncologist; 2020 Aug; 25(8):e1158-e1169. PubMed ID: 32452601
[TBL] [Abstract][Full Text] [Related]
37. Common Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer.
Abad E; García-Mayea Y; Mir C; Sebastian D; Zorzano A; Potesil D; Zdrahal Z; Lyakhovich A; Lleonart ME
Mol Cell Proteomics; 2019 Feb; 18(2):231-244. PubMed ID: 30373788
[TBL] [Abstract][Full Text] [Related]
38. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
Lu Y; Liu Y; Pang Y; Pacak K; Yang C
Pharmacol Ther; 2018 Aug; 188():168-175. PubMed ID: 29621593
[TBL] [Abstract][Full Text] [Related]
39. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Villalona-Calero MA; Duan W; Zhao W; Shilo K; Schaaf LJ; Thurmond J; Westman JA; Marshall J; Xiaobai L; Ji J; Rose J; Lustberg M; Bekaii-Saab T; Chen A; Timmers C
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26848151
[TBL] [Abstract][Full Text] [Related]
40. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer.
Duan W; Gao L; Aguila B; Kalvala A; Otterson GA; Villalona-Calero MA
Front Oncol; 2014; 4():368. PubMed ID: 25566506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
